Showing 5361-5370 of 9401 results for "".
- Dermatologist Named AAD Patient Hero for Providing Skin Care to People Experiencing Homelessness Amid COVID-19https://practicaldermatology.com/news/dermatologist-names-aad-patient-hero-for-providing-skin-care-to-people-experiencing-homelessness-amid-covid-19/2460582/Jennifer Tan, MD, FAAD is an American Academy of Dermatology (AAD) Patient Care Hero for making critical skin care and hygiene items easily accessible to individuals experiencing homelessness during the COVID-19 pandemic. As the state government issued COVID-19 stay-at-home guidanc
- FDA Grants Priority Review for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe ADhttps://practicaldermatology.com/news/fda-grants-priority-review-for-pfizers-abrocitinib-an-oral-once-daily-jak1-inhibitor-for-patients-12-and-up-with-moderate-to-severe-ad/2460580/The U.S. Food and Drug Administration (FDA) has granted Priority Review designation to Pfizer’s New Drug Application (NDA) for abrocitinib (100mg and 200mg), an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, for the treatment of moderate to severe atopic dermatitis (AD) in
- The HydraFacial Company And Circadia Expand Partner Boosters Globallyhttps://practicaldermatology.com/news/the-hydrafacial-company-and-circadia-expand-partner-boosters-globally/2460579/The HydraFacial Company is extending their partnership with Circadia to offer the Chrono-Peptide Booster and ProTec Plus Booster to HydraFacial providers in more than 40 countries. "The Circadia boosters for HydraFacial are already loved by providers and consume
- Arcutis: Phase 1/2b Enrollment Complete for ARQ-252 in Chronic Hand Eczemahttps://practicaldermatology.com/news/arcutis-phase-12b-enrollment-complete-for-arq-252-in-chronic-hand-eczema/2460578/Arcutis Biotherapeutics, Inc. has completed enrollment in the Phase 1/2b studyof its Janus kinase type 1(JAK1) ARQ-252 in adult patients with chronic hand eczema. Arcutis has updated its projected topline data from this trial to mid-2021.
- Soligenix's Phase 3 FLASH Study Continues to Demonstrate Positive Benefits of SGX301 in Cutaneous T-Cell Lymphoma Patientshttps://practicaldermatology.com/news/soligenixs-phase-3-flash-study-continues-to-demonstrate-positive-benefits-of-sgx301-in-cutaneous-t-cell-lymphoma-patients/2460576/Continued optional treatment with Soligenix, Inc.’s SGX301 (synthetic hypericin) demonstrates positive benefits in patients with cutaneous T-Cell lymphoma Nearly half of all patients in Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) trial conti
- Connect Biopharma to Present Additional Positive Results from the Phase 1b Study of CBP-201 for Patients with Moderate-to-Severe AD at EADV Virtual Meetinghttps://practicaldermatology.com/news/connect-biopharma-to-present-additional-positive-results-from-the-phase-1b-study-of-cbp-201-for-patients-with-moderate-to-severe-ad-at-eadv-virtual-meeting/2460574/Connect Biopharma is slated to present the full results from the Phase 1b study of CPB-201, a novel IL-4R&alpha
- Coping with COVID: Most Psoriasis Patients Taking Immunosuppressants Survive COVID-19https://practicaldermatology.com/news/coping-with-covid-most-pso-patients-taking-immunosuppressants-survive-covid-19/2460573/Patients with psoriasis who are taking drugs that affect their immune system have high rates of survival from COVID-19, according to the first findings from a global registry of psoriasis and COVID-19 patients. The initial findings from the PsoProtect registry, which appear in the
- DermOQ To Buy Skin Products's ECHO2 Plus Oxygen Facial Treatment Product Linehttps://practicaldermatology.com/news/dermoq-to-buy-skin-products-incs-echo2-plus-oxygen-facial-treatment-product-line/2460569/DermOQ Inc. is purchasing Skin Products Inc.’s ECHO2 Plus and Oxyceuticals oxygen facial treatment product lines. DermOQ offers its topical oxygen products under the brand names DermOQ Oxygen Lab and
- Eczema Missing Link Found: Researchers ID Protein that Triggers AD by Bacteriahttps://practicaldermatology.com/news/eczema-missing-link-found-researchers-id-protein-that-triggers-ad-by-bacteria/2460567/Second immunoglobulin-binding protein (Sbi) is a unique trigger of eczema by Staphylococcus aureus, according to research in the Journal of Allergy and Clinical Immunology. Sbi induces rapid release of Interleukin-33, a key component of the immune response in childhood ecz
- ADCS Acquires Montgomery Dermatology; Catawba Research Enters Partnershiphttps://practicaldermatology.com/news/adcs-acquires-montgomery-dermatology-catawba-research-enters-partnership/2460565/Advanced Dermatology and Cosmetic Surgery (ADCS), the largest dermatology practice in the US, has acquired Dermatology Associates of Montgomery, a leading dermatology practice based in the Southeast. Bundy Group served as exclusive financial advisor to Dr. Steve Maddox, owner of Dermatology